Form 4: Director William H. Dunn Jr. Acquires Stock Options in Prothena Corp

William H. Dunn Jr., a director of Prothena Corp, reports the acquisition of stock options for 15,000 ordinary shares.

Summary

• On May 15, 2024, William H. Dunn Jr., a director of Prothena Corp Public Ltd Co, acquired stock options for 15,000 ordinary shares.
• The exercise price of these options is $22.39.
• The options vest on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025, assuming continuous service as a director.
• The options expire on May 15, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule, contingent on continued service, aligns with standard practices to incentivize long-term commitment.
• The exercise price of $22.39 would need to be compared to the current market price of PRTA to assess the immediate value of the options.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates